The scientific goals of the Genetic Mechanisms Program are to define and understand the genetic changes that occur during cancer development, to understand the genesis of those changes, and to use gene transfer technology to treat cancer. These goals include defining the specific changes that drive tumor initiation and progression, lead to resistance to tumor treatment, and influence cancer susceptibility. To achieve these goals, we feature strong research programs focused on the following Aims: 1) To identify cancer susceptibility genes, DNA mutators, and drivers of metastasis to develop new biomarkers for cancer progression and drug targets for therapeutic intervention; 2) To understand the mechanisms that maintain genome stability, including pathways that control replication stress and DNA damage tolerance; and 3) To develop a new generation of viral and nonviral cancer therapeutics that will be tested in preclinical animal models. The Genetic Mechanisms Program is a basic science program led by Anja-Katrin Bielinsky, PhD, and new co-leader Masato Yamamoto, MD, PhD, and has 43 members, representing 19 departments and 8 schools or colleges. Dr. Bielinsky oversees the early phases of translation, and Dr. Yamamoto assists with later phases and facilitates active collaborations with clinicians outside GM who are experts in clinical trials. For the last budget year, GM members were supported by $2.9 million in direct costs from the National Cancer Institute, other NIH funding totaled $7.2 million, total peer-reviewed funding was $10.95 million, and cancer-related funding from all sponsored sources totaled $15.2 in direct costs. Since 2013, Program members have published 634 papers, 17% of which resulted from intraprogrammatic collaborations, 20% from interprogrammatic collaborations, and 85% from external collaborations. Over the past funding cycle, we enhanced our team-building efforts to promote research in areas that span multiple themes. Uncovering the mechanisms that promote drug resistance in solid tumors is one such area that aligns strongly with the Masonic Cancer Center Strategic Plan Scientific Priority for Growth (SPG2) of enhancing functional genomics strategies to further our understanding of cancer and develop new therapeutic avenues. Major accomplishments include 1) validation of novel biomarkers that predict progression-free survival in solid tumors, 2) uncovering druggable targets in osteosarcoma, 3) generating functional genomics pipelines that allow for the systematic identification of drug- resistance pathways, and 4) generating a second-generation suite of oncolytic viruses that will improve treatment of patients in our catchment area. The Masonic Cancer Center has provided substantial value to the Program, including access to shared resources, recruitment of new faculty, funding of 26 pilot projects for nearly $1M, annual research retreats, monthly Program meetings, weekly seminars, and a weekly newsletter to facilitate collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-22
Application #
9859368
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Regan Anderson, Tarah M; Ma, Shihong; Perez Kerkvliet, Carlos et al. (2018) Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis. Mol Cancer Res 16:1761-1772
Santiago, Victor; Lazaryan, Aleksandr; McClune, Brian et al. (2018) Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma 59:958-966
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Boatman, Jeffrey A; Vock, David M; Koopmeiners, Joseph S et al. (2018) Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. Biostatistics 19:103-118
Guo, Jingshu; Villalta, Peter W; Weight, Christopher J et al. (2018) Targeted and Untargeted Detection of DNA Adducts of Aromatic Amine Carcinogens in Human Bladder by Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry. Chem Res Toxicol :
Teitelbaum, A M; Murphy, S E; Akk, G et al. (2018) Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. Pharmacogenomics J 18:136-143
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. Br J Haematol 182:887-894
Bellamri, Medjda; Xiao, Shun; Murugan, Paari et al. (2018) Metabolic Activation of the Cooked Meat Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine in Human Prostate. Toxicol Sci 163:543-556
Murphy, Sharon E; von Weymarn, Linda B; Parenteau, Marc et al. (2018) Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers. Chem Res Toxicol 31:168-175
Hegerova, Livia; Bachan, Adam; Cao, Qing et al. (2018) Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 24:e20-e25

Showing the most recent 10 out of 1013 publications